New Cholesterol Guidelines: Lp(a) Test & Earlier Treatment Recommended

Recent guidelines released Friday by the American Heart Association and the American College of Cardiology are calling for a more proactive and earlier approach to managing high cholesterol, including a recommendation for all adults to undergo a one-time screening for lipoprotein(a). This genetic marker, increasingly recognized for its role in cardiovascular risk, is prompting a shift towards more personalized and preventative strategies.

Expanding the Toolkit for Cardiovascular Risk Assessment

Cardiovascular disease remains the leading cause of death for both men and women in the United States. These updated guidelines, published in Circulation and JACC, the Journal of the American College of Cardiology , aim to broaden the tools available to clinicians for assessing an individual’s risk and determining the most appropriate course of action. The guidelines consolidate evidence-based recommendations, effectively retiring and replacing the 2018 Guideline on the Management of Blood Cholesterol.

Traditionally, LDL cholesterol – often referred to as “bad” cholesterol – has been a primary focus in cardiovascular risk assessment. However, experts now recognize that a more comprehensive picture is needed. “Measuring additional biomarkers can give a more complete picture of someone’s cardiovascular risk and help inform decisions about whether lipid-lowering therapy is needed sooner rather than later,” explained Dr. Roger Blumenthal, a cardiologist at Johns Hopkins and chair of the guideline writing committee, in a statement.

Lipoprotein(a): A Genetic Component of Heart Disease Risk

The inclusion of a one-time lipoprotein(a) test for all adults is a significant change. This simple blood test, becoming increasingly available in primary care settings, identifies individuals with a genetically determined predisposition to heart disease. Because lipoprotein(a) levels are relatively stable throughout life, a single measurement is generally sufficient, ideally performed early in adulthood. Elevated levels indicate an increased inherited risk of heart attacks, strokes, and other cardiovascular events.

This isn’t simply about identifying risk, but about understanding it at a deeper level. As Dr. Steven Nissen, a preventive cardiologist at Cleveland Clinic, noted, “These new guidelines will result in more people being treated earlier.”

Beyond Lipoprotein(a): Refining Risk Prediction

The guidelines also advocate for wider use of coronary calcium scoring, a non-invasive scan that detects calcified plaque in the arteries. This provides a more direct measure of existing atherosclerosis. The updated guidelines recommend utilizing the PREVENT-ASCVD equations, rather than the older Pooled Cohort Equations, for 10- and 30-year risk assessment in adults aged 30 to 79. These newer equations are designed to provide a more accurate prediction of cardiovascular risk and guide decisions regarding lipid-lowering therapy.

The PREVENT-ASCVD equations are particularly relevant for primary prevention – that is, for individuals who have not yet experienced a cardiovascular event. The guidelines suggest that LDL-lowering therapy may be reasonable for those with a borderline 10-year risk estimate of 3% to less than 5%, and is recommended for those with an intermediate risk of 5% to less than 10%, following a thorough discussion between the clinician and patient.

Early Intervention: A Focus on Youth and Family History

A key emphasis of the new guidelines is earlier intervention, starting in childhood. The document highlights the importance of healthy lifestyle changes from a young age. Pharmacotherapy – the use of medications – is also recommended for youth with familial hypercholesterolemia (FH), a genetic condition causing very high cholesterol levels, and for young adults with LDL cholesterol levels of 160 mg/dL or higher, or a strong family history of premature atherosclerotic cardiovascular disease (ASCVD).

Statins Remain Central, But Approach Evolves

While the guidelines introduce new tools and strategies, cholesterol-lowering drugs, particularly statins, remain the cornerstone of treatment for high cholesterol. However, the framework suggests a potential broadening of statin use. Medications may now be considered even for patients with relatively low risk, if their overall lifetime risk profile warrants it. This reflects a growing understanding that cumulative risk over a lifetime is a crucial factor in determining the need for intervention.

The accessibility of generic statins – with many prescriptions costing around $3 per month – further supports their widespread use. It’s estimated that approximately 25% of adults in the U.S. Have elevated LDL cholesterol levels, making this a significant public health concern.

What’s Next: Implementation and Ongoing Research

The release of these guidelines marks an critical step, but the real work lies in implementation. Healthcare providers will need to familiarize themselves with the new recommendations and integrate them into their clinical practice. This will likely involve education and training initiatives to ensure consistent application of the guidelines.

Further research is also needed to refine risk prediction models and evaluate the long-term impact of these new strategies. Ongoing surveillance of cardiovascular disease rates and treatment patterns will be essential to assess the effectiveness of the guidelines and identify areas for improvement. The American Heart Association and American College of Cardiology will likely continue to update the guidelines as new evidence emerges.

these updated guidelines represent a shift towards a more proactive, personalized, and preventative approach to managing cholesterol and reducing the burden of cardiovascular disease. The emphasis on early intervention, comprehensive risk assessment, and the incorporation of genetic markers like lipoprotein(a) offers the potential to significantly improve cardiovascular health for millions of Americans. For more information on heart health, consult resources from the American Heart Association and the Centers for Disease Control and Prevention.